Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in Maine: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 214 | 39% |
| 2020 | 3 | 152 | 46% |
| 2021 | 4 | 209 | 51% |
| 2022 | 1 | 146 | 56% |
| 2023 | 2 | 145 | 59% |
| 2024 | 0 | 161 | 62% |
| 2025 from claims | – | 435 351–510 | 63% |
| 2026 forecast | – | 480 376–603 | 63% |
| 2027 forecast | – | 522 387–690 | 64% |
| 2028 forecast | – | 567 402–783 | 64% |
| 2029 forecast | – | 616 419–884 | 65% |
| 2030 forecast | – | 669 438–993 | 65% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 23 | 1,666−3.1%/yr | −3.1%/yr | 1.2 | 0% | 1,760 in 2030+0.9%/yr |
| New York | 32 | 1,508−6.4%/yr | −6.4%/yr | 0.8 | 0% | 1,510 in 20300%/yr |
| New Jersey | 26 | 1,073−1.9%/yr | −1.9%/yr | 1.0 | 0% | 1,090 in 2030+0.2%/yr |
| Massachusetts | 18 | 984−3.3%/yr | −3.3%/yr | 1.0 | 0% | 1,170 in 2030+2.9%/yr |
| Connecticut | 1 | 337−3.8%/yr | −3.8%/yr | 1.0 | 0% | 320 in 2030−1%/yr |
| New Hampshire | 4 | 267−3.3%/yr | −3.3%/yr | 1.2 | 0% | 360 in 2030+5.1%/yr |
| Rhode Island | 3 | 142+2.9%/yr | +2.9%/yr | 1.5 | 0% | 70 in 2030−11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 4 | 340−15%/yr | −15%/yr | 2.20.4× | 5% | 390 in 2030+2.3%/yr |
| Peripheral arterial intervention | 1 | 250−14%/yr | −14%/yr | 1.50.3× | 0% | 260 in 2030+0.5%/yr |
| Superficial venous ablation | 3 | 188−9.3%/yr | −9.3%/yr | 1.10.3× | 100% | 430 in 2030+15%/yr |
Carotid revascularization in every state, and its device makers · Every procedure market in Maine · Every state · Compare with Pennsylvania
Boston Scientific leads with 100% of company spending on these surgeons in 2025, level with 2024.
In 2025, 2 companies reported engagement with Maine’s surgeons worth $72K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.